Interpace Biosciences (OTCMKTS:IDXG) versus Ramsay Health Care (OTCMKTS:RMSYF) Head to Head Contrast

Institutional & Insider Ownership

5.7% of Interpace Biosciences shares are owned by institutional investors. Comparatively, 13.2% of Ramsay Health Care shares are owned by institutional investors. 0.9% of Interpace Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Interpace Biosciences and Ramsay Health Care”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Interpace Biosciences	$38.73 million	0.17	$24.58 million	$0.08	19.04
Ramsay Health Care	N/A	N/A	N/A	$1.43	20.69

Interpace Biosciences has higher revenue and earnings than Ramsay Health Care. Interpace Biosciences is trading at a lower price-to-earnings ratio than Ramsay Health Care, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Interpace Biosciences and Ramsay Health Care’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Interpace Biosciences	67.64%	145.40%	87.36%
Ramsay Health Care	N/A	N/A	N/A

Summary

Interpace Biosciences beats Ramsay Health Care on 5 of the 8 factors compared between the two stocks.

About Interpace Biosciences

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

About Ramsay Health Care

Ramsay Health Care Limited owns and operates hospitals. The company offers health care services to public and private patients. It operates facilities in approximately 530 locations in the Asia Pacific, the United Kingdom, France, and Nordics. Ramsay Health Care Limited was founded in 1964 and is based in Sydney, Australia.